Back to Feed
ClinicalTrials.gov|Clinical Trial
CAR-T Therapy for Refractory Autoimmune Diseases
LiangZou
Abstract
This study is an investigator-initiated single center, single arm clinical study with a target population of patients with refractory autoimmune diseases. It is an early exploratory clinical study of the safety, tolerability and initial efficacy of CD19 CAR-T in the treatment of refractory autoimmune diseases. Phase: NA Status: RECRUITING Conditions: Autoimmune Diseases Interventions: JY231 (JY231 injection)
Keywords
Autoimmune Diseases